KeyCorp Free cash flow decreased by 111.0% to -$74.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 50.7%, from -$150.00M to -$74.00M. Over 3 years (FY 2021 to FY 2025), Free cash flow shows an upward trend with a 22.9% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
An increase suggests improved operational efficiency or reduced capital intensity, providing more flexibility for capital allocation. A decrease may indicate higher investment in R&D or infrastructure, or potential challenges in converting earnings into cash.
Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and m...
Large-cap medical device and pharmaceutical peers typically maintain strong, positive free cash flow, though levels vary based on the intensity of R&D spending and the lifecycle stage of major product lines.
free_cash_flow| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $433.00M | $916.00M | $0.00 | $863.00M | $0.00 | $2.06B | $1.55B | $694.00M | $532.00M | $541.00M | $994.00M | $347.00M | -$1.22B | $1.70B | -$150.00M | $1.21B | $367.00M | $673.00M | -$74.00M |
| QoQ Change | — | +111.5% | -100.0% | — | -100.0% | — | -24.8% | -55.2% | -23.3% | +1.7% | +83.7% | -65.1% | -452.2% | +239.4% | -108.8% | +907.3% | -69.7% | +83.4% | -111.0% |
| YoY Change | — | — | — | — | -100.0% | +125.1% | — | -19.6% | — | -73.8% | -35.9% | -50.0% | -325.9% | +71.4% | -143.2% | — | +130.0% | -60.5% | +50.7% |